Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 5/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | STK4 | Q13043 | 1/20 | 0.30 |
| ▸ | STK3 | Q13188 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918522 | 0.82 | CSF1R (0.38) | CSF1REGFRSTK4 | |
| SCHEMBL9918517 | 0.77 | RET (0.35) | JAK2LRRK2JAK1TYK2EGFR | |
| SCHEMBL9918545 | 0.77 | CSF1R (0.46) | CSF1RLRRK2 | |
| SCHEMBL9918523 | 0.75 | MAPT (0.41) | CSF1REGFR | |
| SCHEMBL9921764 | 0.74 | MEN1 (0.40) | CSF1R | |
| SCHEMBL9918539 | 0.73 | CSF1R (0.36) | CSF1RLRRK2EGFRCIT | |
| SCHEMBL12833307 | 0.69 | LRRK2 (0.43) | CSF1RLRRK2 | |
| SCHEMBL9918524 | 0.69 | TTBK1 (0.41) | CSF1RLRRK2 | |
| SCHEMBL9918540 | 0.69 | EGFR (0.42) | CSF1RJAK2JAK1MAPK8MAPK14 | |
| SCHEMBL9918558 | 0.68 | HTT (0.41) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CSF1R 410/4885JAK2 1/4885LRRK2 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.